Bone marrow suppression in the setting of normal thiopurine methyltransferase phenotype testing.
Best
Chad
C
Department of Pediatrics, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA. bestx051@umn.edu
Sudel
Boris
B
D000293:Adolescent; D000505:Alopecia / Q000139:chemically induced; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects* / Q000276:immunology; D003424:Crohn Disease / Q000188:drug therapy* / Q000201:enzymology* / Q000276:immunology; D004342:Drug Hypersensitivity / Q000175:diagnosis; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015122:Mercaptopurine / Q000009:adverse effects*; D019804:Mesalamine / Q000009:adverse effects*; D008780:Methyltransferases / Q000378:metabolism*; D010198:Pancytopenia / Q000139:chemically induced; D010641:Phenotype; D011686:Purine-Pyrimidine Metabolism, Inborn Errors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; D019804:Mesalamine; D015122:Mercaptopurine; D008780:Methyltransferases; C022745:thiopurine methyltransferase